January 27, 2023 – Horsham, PA-based Klein Hersh Worldwide, an govt search agency targeted on the life sciences and healthcare industries, has positioned Jane Pritchett Henderson as chief monetary officer of biotechnology firm Apogee Therapeutics, which supplies therapies for immunological and inflammatory issues. Ms. Henderson has an intensive monitor report in monetary and company technique management, together with financing personal and public corporations, partnering and M&A, and constructing groups and operations. She beforehand served as CFO and chief enterprise officer at Invivyd Therapeutics the place she led the corporate’s Collection C crossover financing and subsequent IPO.
“Jane is a extremely completed chief and a number of time CFO with vital experience in company technique and finance within the healthcare sector, and we’re excited to welcome her to our management group,” stated Dr. Michael Henderson, CEO of Apogee Therapeutics. “Her distinctive mixture of expertise as a seasoned biopharmaceutical govt and funding banker will assist propel Apogee ahead in its mission to advance medicines to the clinic for sufferers residing with a spread of immunological circumstances.”
Ms. Henderson has a mix of greater than 34 years’ expertise in rising private and non-private biopharmaceutical corporations and funding banking, in addition to intensive board expertise. Ms. Henderson has held govt management roles in finance and company growth at quite a few private and non-private biotechnology corporations together with Invivyd Therapeutics (previously Adagio Therapeutics), Turnstone Biologics, Voyager Therapeutics, Kolltan Prescribed drugs (acquired by Celldex) and ISTA Prescribed drugs (acquired by Bausch + Lomb). As well as, Ms. Henderson has intensive healthcare funding banking expertise together with the execution of greater than 95 mergers and acquisitions and financing offers throughout varied senior roles at HSBC Holdings, Canadian Imperial Financial institution of Commerce, Lehman Brothers, and Salomon Brothers.
Higher Therapy Choices
“I’m keen about working with corporations that may change the lives of sufferers, and Apogee has made spectacular progress in rapidly advancing a therapeutics pipeline that has the potential to offer higher remedy choices for sufferers and their physicians,” stated Ms. Henderson. “I sit up for partnering with Michael and the group and leveraging my expertise to drive Apogee’s monetary technique and maximize shareholder worth whereas progressing our lead candidate, APG777, towards the clinic.”
The appointment of Ms. Henderson comes within the wake of Apogee’s announcement of a $149 million Collection B financing in December. The financing was co-led by Deep Monitor Capital and RTW Investments. Different buyers included funds and accounts suggested by Constancy Administration & Analysis Firm, OrbiMed, Perceptive Xontogeny Ventures Fund II, RA Capital Administration, and Wellington Administration. Founding buyers, Fairmount and Venrock Healthcare Capital Companions, additionally participated within the oversubscribed Collection B financing.
Apogee Therapeutics is constructing a pipeline of product candidates focusing on clinically validated biology and well-established growth pathways. The corporate was based in 2022 by Fairmount and Venrock Healthcare Capital Companions and is backed by main healthcare buyers. By a strategic partnership with Paragon Therapeutics, Apogee has the choice for unique growth and industrial rights to a collection of top-tier antibodies which have been particularly engineered to focus on among the largest and highest unmet wants going through folks with immunological and inflammatory issues. Apogee intends to file a minimum of one Investigational New Drug (IND) utility with the U.S. Meals and Drug Administration every year over the following three years, starting in 2023, and anticipates offering extra data on its 4 pipeline applications subsequent 12 months.
Life Sciences and Healthcare Targeted
Established in 1998, Klein Hersh works with international pharmaceutical, biotech, and healthcare corporations in addition to working companies of PE and VC-backed investments. Among the many agency’s purchasers are a Who’s Who checklist of biopharma, biotechnology, life sciences, healthcare, therapeutics, and enterprise capital & personal fairness considerations, together with CVS Well being, Andreesen Horowitz, Elevate Bio, KKR, Novo Holdings, Talaris Therapeutics, Atlas Enterprise, Veradigm, Versant, Cognizant, Francisco Companions, Madrigal Prescribed drugs, Adicet Bio, Arvinas, Third Rock, Riverside, Signet Healthcare Companions, Black Diamond Therapeutics, Clear Alternative, Limelight Bio, and Rhythm Prescribed drugs, amongst others.
In 2021, New State Capital Companions, based mostly in Larchmont, NY, took an fairness funding stake in Klein Hersh. New State is an entrepreneurial-minded personal fairness agency that prides itself on a long-term outlook, approaching every potential funding as a possibility to create lasting and priceless relationships with firm founders and particularly impartial sponsors. The agency has the flexibility to take a position as much as $100 million in fairness per transaction and seeks to spend money on market-leading corporations with $8 million to $40 million of EBITDA within the areas of enterprise companies, industrials, and shopper.
Associated: Personal Fairness Agency Takes Majority Stake in Bullhorn
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media
